'Site-less' trials in mind, Novartis launches an app for ophthalmology research
In the latest company move to embrace all things digital, Novartis has launched an app that it hopes will boost participation in its ophthalmology trials.
The pharma giant is calling the tech FocalView, and it’ll be used by researchers to track disease progression in patients with ophthalmic disease real-time. Patients will self-report data through the app that will guide clinical research, starting by taking assessments like visual acuity and contrast sensitivity tests.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.